Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 6/20 | 0.49 |
| ▸ | MTOR | P42345 | 2/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 4/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.48 |
| ▸ | PIK3C2B | O00750 | 1/20 | 0.48 |
| ▸ | CCNE2 | O96020 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | PRKACG | P22612 | 1/20 | 0.48 |
| ▸ | PRKACB | P22694 | 1/20 | 0.48 |
| ▸ | CCNE1 | P24864 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | KDR | P35968 | 1/20 | 0.48 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.43 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 2/20 | 0.37 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.37 |
| ▸ | HSD17B1 | P14061 | 5/20 | 0.37 |
| ▸ | HSD17B2 | P37059 | 5/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1093172 | 0.87 | PIK3CA (0.50) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093085 | 0.86 | PIK3CA (0.49) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093523 | 0.86 | PIK3CA (0.49) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093962 | 0.84 | PIK3CA (0.57) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093037 | 0.84 | PIK3CA (0.49) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1092766 | 0.84 | PIK3CA (0.47) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093484 | 0.84 | PIK3CA (0.47) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL17473689 | 0.82 | PIK3CA (0.44) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1092750 | 0.82 | PIK3CA (0.49) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B | |
| SCHEMBL1093919 | 0.80 | PIK3CA (0.52) | PIK3CAMTORPIK3CGPIK3CBPIK3C2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2035431-B1 | THIENO[3,2-D]PYRIMIDINES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE FOR THE TREATMENT OF CANCER DISEASES | HOFFMANN LA ROCHE (CH) | 2016-02-03 | — | — | EP | claimed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | claimed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | claimed |
| EP-2035431-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-18 | — | — | EP | claimed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | claimed |
| EP-2035431-B1 | THIENO[3,2-D]PYRIMIDINES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE FOR THE TREATMENT OF CANCER DISEASES | HOFFMANN LA ROCHE (CH) | 2016-02-03 | — | — | EP | disclosed |
| EP-2035431-B1 | THIENO[3,2-D]PYRIMIDINES AS INHIBITORS OF PHOSPHATIDYLINOSITOL-3-KINASE FOR THE TREATMENT OF CANCER DISEASES | HOFFMANN LA ROCHE (CH) | 2016-02-03 | — | — | EP | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-8153639-B2 | kinase inhibitor; immunotherapy; viricides; function or behavior associated with PI3 kinase such as cancer, immune, cardiovascular, nervous system, metabolism/endocrine and neurological diseases, viral infection, inflammation; 3-(4-Pyridin-4-yl-thieno[3,2-d]pyrimidin-2-yl)-phenol | F. HOFFMAN-LA ROCHE AG (CH) | 2012-04-10 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2009-08-20 | — | — | US | disclosed |
| EP-2035431-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2009-03-18 | — | — | EP | disclosed |
| WO-2007132171-A1 | PHARMACEUTICAL COMPOUNDS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-11-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090209559-A1 | PHARMACEUTICAL COMPOUNDS | PIK3CA, JAK2, PIK3CD | PIK3CA 1/4885MTOR 16/4885PIK3CG 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.